
GSK Acquires Vaccine Platform Tech Company Okairos
GSK expands its vaccines platform technology expertise by acquiring Okairos, a Swiss-based company.
GlaxoSmithKline (GSK announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for $325 million, the company stated in a
Under the terms of the transaction, GSK will take full ownership of Okairos and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus (RSV), hepatitis C virus (HCV), malaria, tuberculosis, ebola, and HIV, supplementing the company’s existing vaccines pipeline. Okairos’ platform technology is based on novel viral vectors (mechanisms which deliver genetic material into cells) that are designed to help stimulate immune responses (in particular T-cells) and aim to protect against and treat infectious diseases and cancer. The potential of this technology has been tested in clinical studies in which more than 700 subjects have been vaccinated, including Phase II programs in hepatitis C and malaria.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.